ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1158

Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis

Chan Mi Lee1, Maricela Haghiac2 and Marina Magrey3, 1University Hospitals, Cleveland, OH, 2Metrohealth Medical Center, Cleveland, OH, 3Case Western Reserve University, University Hospitals, Richfield, OH

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), gender, Inflammation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: S100 proteins are a family of 25 calcium-binding cytosolic proteins which are involved in stress and inflammatory responses. S100A4 acts as a negative regulator of bone formation, where previous studies have shown increased plasma levels of S100A4 in patients with axial spondyloarthritis (axSpA) and higher in those without syndesmophytes. The S100A4 levels inversely correlated with disease duration and had a weak inverse correlation with radiographic damage. Similarly, S100A12 is one of the phagocyte-specific inflammatory S100 proteins which activate intracellular pro-inflammatory pathways via receptor for advanced glycation end products (RAGE). Given that ankylosing spondylitis (AS) is more frequently diagnosed and presents with higher radiological progression in men, we compared the plasma levels of S100A4 and S100A12 in male versus female patients with AS to better understand the molecular mechanisms behind the gender difference.

Methods: Peripheral blood samples (30mL) were obtained from 13 female and 14 male subjects ≥18 years of age with AS based on modified New York diagnostic criteria as well from 14 control subjects at the Clinical Research Unit of MetroHealth Medical Center per approved IRB protocol. Plasma was separated by immediate centrifugation following blood collection in EDTA-containing tubes and S100A4 and S100A12 were measured by ELISA kit CircuLex (MBL Life Science). Statistical analyses were performed by one-way ANOVA or Kruskal-Wallis test with appropriate post-tests, with statistical significance set at P < 0.05.

Results: There was no difference in male versus female AS cohort, including overall disease burden (Table 1). However, plasma levels of S100A4 were significantly elevated in female patients only, not in the male patients. On the other hand, plasma levels of S100A12 showed an opposite pattern, where it was more elevated in males (Figure 1). Consistent with previous findings of S100A4 acting as a negative regulator of bone formation, sub-analysis of arbitrary ‘High’ versus ‘Low’ S100A4 groups of female patients by S100A4 levels and disease burden showed that higher levels of S100A4 tended to be associated with lower disease burden (Figure 2).

Conclusion: In this preliminary analysis, we show that male and female AS patients may have differing inflammatory mediators. Similar to the previous study which showed an increased circulating levels of S100A4 in AS patients especially during the early stages, we have found that S100A4 levels are elevated in female AS patients, with higher levels associated with less radiographic progression.

Supporting image 1

Patient Cohort Demographics and Disease Activity

Supporting image 2

Differential plasma levels of S100A4 and S100A12 by gender in patients with AS.

Supporting image 3

Comparison of disease severity scores by high versus low levels of S100A4 in female patients with AS.


Disclosures: C. Lee, None; M. Haghiac, None; M. Magrey, AbbVie, Eli Lilly, Novartis, Pfizer Inc, UCB.

To cite this abstract in AMA style:

Lee C, Haghiac M, Magrey M. Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differential-plasma-levels-of-s100-proteins-in-male-versus-female-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-plasma-levels-of-s100-proteins-in-male-versus-female-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology